ADOCIA Announces its Financial Calendar for 2025
19 Décembre 2024 - 6:00PM
Business Wire
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical company focused on the research and development
of innovative therapeutic solutions for the treatment of diabetes
and obesity, today announced its financial calendar for 2025.
February 25, 2025
Publication of revenue for Q4 2024
April 17, 2025
Publication of 2024 financial
statements
May 14, 2025
Publication of revenue for Q1 2025
June 11, 2025
Annual shareholders’ meeting
July 23, 2025
Publication of revenue for Q2 2025
September 25, 2025
Publication of mid-year financial
statements as of June 30, 2025
October 15, 2025
Publication of revenue for Q3 2025
In addition to regular meetings with the financial community,
investors can also find updated information on the company’s
website (www.adocia.com).
All corporate information on the company such as its financial
statements, its corporate presentation and its status is available
on the company’s website, in the Investors’ section “Regulated
Information”.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining different hormones; 2) AdOral®, an oral peptide
delivery technology; 3) AdoShell®, an immunoprotective biomaterial
for cell transplantation, with an initial application in pancreatic
cells transplantation; and 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 80 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241219542517/en/
Adocia
Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
Adocia Press & Investor Relations Bruno Arabian
Nicolas Entz
adocia@ulysse-communication.com + 33 (0)6 87 88 47 26
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
